Symbol | Exchange | Currency |
|---|
Vaccinex, Inc. (Nasdaq: NASDAQ:VCNX) today announced the initiation of a single-arm open label, Phase Ib/2 study to evaluate pepinemab in combination with avelumab as second line...
Vaccinex, Inc. (Nasdaq: NASDAQ:VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the...
Investing.com - Vaccinex (NASDAQ:VCNX) reported on Monday third quarter earnings that beat analysts' forecasts and revenue that topped expectations. Vaccinex announced earnings...
Vaccinex, Inc. (NASDAQ:VCNX) announced that it has achieved full enrollment in an early-stage study on its lead pipeline candidate pepinemab (VX15/2503). The study is evaluating...
The future of medicine may have to wait; Vaccinex Inc (NASDAQ:VCNX), a biotech company pioneering biotherapeutics that it hopes will treat grave diseases like cancer, is struggling...
Vaccinex, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate, pepinemab (VX15/2503), is a humanized monoclonal antibody that binds and blocks the signaling activity of semaphorin 4D (SEMA4D). It is focused on the development of pepinemab for the treatment of certain cancer indications, in particular, head and neck squamous cell carcinoma (HNSCC) as well as neurodegenerative diseases, including Huntington's disease (HD), and Alzheimer's disease, (AD). The Company has discovered VX5 using its ActivMAb antibody discovery platform. VX5 is a human antibody to CXCL13, a molecule that regulates the formation of immune tissues, and is in preclinical development for the treatment of multiple sclerosis (MS) and for other autoimmune disorders.
| Average | 7.000 (+1,607.317% Upside) |
| High | 7.000 |
| Low | 7.000 |
| Price | 0.410 |
| No. of Analysts | 1 |
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Buy | Strong Buy | Buy | Sell | Strong Sell |
| Technical Indicators | Strong Buy | Strong Buy | Strong Buy | Strong Sell | Strong Sell |
| Summary | Strong Buy | Strong Buy | Strong Buy | Strong Sell | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 190.41 | 192.36 | 187.15 | -1.81 | -0.94% | 115.62M | NASDAQ | |||
| 160.25 | 160.34 | 157.85 | +1.32 | +0.83% | 56.97M | NASDAQ | |||
| 60.90 | 61.01 | 59.91 | +0.98 | +1.64% | 12.65M | NYSE | |||
| 206.01 | 207.58 | 203.55 | +1.73 | +0.85% | 27.63M | NASDAQ | |||
| 105.44 | 105.49 | 103.84 | -0.16 | -0.15% | 30.02M | NASDAQ | |||
| 280.57 | 280.63 | 275.28 | +2.91 | +1.05% | 28.01M | NASDAQ | |||
| 40.39 | 40.46 | 39.87 | +0.21 | +0.52% | 17.13M | NYSE | |||
| 97.95 | 99.52 | 96.74 | -2.33 | -2.32% | 64.14M | NASDAQ | |||
| 98.13 | 98.30 | 96.40 | -0.58 | -0.59% | 55.74M | NASDAQ | |||
| 156.56 | 158.27 | 153.56 | -3.42 | -2.14% | 2.51M | NASDAQ | |||
| 267.79 | 271.67 | 263.55 | -4.12 | -1.52% | 45.08M | NASDAQ | |||
| 8.20 | 8.35 | 8.06 | -0.13 | -1.56% | 17.94M | NYSE | |||
| 106.07 | 106.16 | 104.74 | -0.18 | -0.17% | 25.05M | NASDAQ | |||
| 44.98 | 45.58 | 44.24 | -0.81 | -1.77% | 11.16M | NYSE | |||
| 50.51 | 50.55 | 49.49 | +0.78 | +1.57% | 19.26M | NASDAQ |